Belantamab Mafodotin Mechanism of Action: Explaining Induction of Immunogenic & Inflammatory Cell Death to Remodel the Tumour Microenvironment in Patients

• Highlighting the importance of in-depth translational characterisation of late-stage ADC assets to understand clinical success
• Explaining how belantamab Mafodotin mechanism of action enables durable patient responses in the clinic
• Laying out lessons learnt that can influence how subsequent and future ADCs are designed

Speakers:

Sue Griffin

Vice President, Translational Haematology & Tumour Omics, Oncology Translational Research

GSK